Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
89bio reports news as a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases. Its recurring updates center on pegozafermin, an engineered fibroblast growth factor 21 analog using glycoPEGylated technology, and its clinical development for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
Company news also covers operating and financial results, clinical and regulatory disclosures, investor conference participation, Nasdaq inducement equity grants, governance matters, material agreements and capital-structure updates tied to its public-company status.
89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), has announced a public offering of 2,200,000 shares of its common stock, with an option for underwriters to purchase an additional 330,000 shares. Proceeds will support the acceleration of its BIO89-100 programs for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The offering is contingent on market conditions, and full details will be available in the prospectus.
89bio, Inc. (Nasdaq: ETNB) announced its Q1 2020 financial results, reporting a net loss of $10.5 million compared to $4.4 million in Q1 2019. The increase in loss is linked to higher R&D expenses of $7.8 million, up from $4.3 million a year earlier, and G&A expenses rising to $2.9 million from $0.5 million. The company closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled, expecting topline results in 2H20. Additionally, the FDA cleared its IND application for BIO89-100 targeting severe hypertriglyceridemia, paving the way for a Phase 2 trial when conditions allow.
89bio, a clinical-stage biopharmaceutical company focused on liver and cardio-metabolic diseases, announces CEO Rohan Palekar’s participation in upcoming conferences. He will speak at the BofA Securities 2020 Virtual Global Healthcare Conference on May 14, 2020, at 11:00 AM ET and at the RBC Capital Markets 2020 Global Healthcare Virtual Conference on May 20, 2020, at 3:05 PM ET. The presentations will be accessible live and as an archived webcast on the company’s website, enhancing investor engagement. The lead product candidate, BIO89-100, targets NASH treatment.